Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Palantir Bioceuticals stock

IFAN
US45173B1017
A12GSL

Price

0.00
Today +/-
+0
Today %
+0 %

Palantir Bioceuticals stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Palantir Bioceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Palantir Bioceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Palantir Bioceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Palantir Bioceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Palantir Bioceuticals Stock Price History

DatePalantir Bioceuticals Price
1/17/20250.00 undefined
1/15/20250.00 undefined
1/14/20250.00 undefined
1/13/20250.00 undefined
1/7/20250.00 undefined
1/3/20250.00 undefined
12/31/20240.00 undefined
12/30/20240.00 undefined
12/27/20240.00 undefined
12/26/20240.00 undefined

Palantir Bioceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Palantir Bioceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Palantir Bioceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Palantir Bioceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Palantir Bioceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Palantir Bioceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Palantir Bioceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Palantir Bioceuticals’s growth potential.

Palantir Bioceuticals Revenue, EBIT and net profit per share

DatePalantir Bioceuticals RevenuePalantir Bioceuticals EBITPalantir Bioceuticals Net Income
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20150 undefined-2.16 M undefined-2.38 M undefined
20140 undefined-42,800 undefined-41,800 undefined
20130 undefined-19,210 undefined-19,210 undefined
20120 undefined-18,220 undefined-18,220 undefined
20110 undefined-3,150 undefined-3,150 undefined
20100 undefined-1,470 undefined-1,470 undefined

Palantir Bioceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
20102011201220132014201520212022
00000000
--------
--------
00000000
00000-200
--------
1.421.421.421.020.720.0800
--------
Details

Keystats

Revenue and Growth

The Palantir Bioceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Palantir Bioceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (k)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (k)TANGIBLE ASSETS (k)LONG-T. INVEST. (k)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (k)PROVISIONS (k)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20102011201220132014201520212022
               
040.191.360137.8500
00000000
00000000
00000000
000086.628.7600
040.191.3686.62146.6100
00000200
0000164.52000
0000010000
00000.034.7700
00000000
000005.3200
00000.194.8700
00000.285.0200
               
00.010.010.010.080.090.791
0000.01-0.035.956.626.62
-0-0-0.02-0.04-0.08-2.46-7.41-7.62
00000000
00000000
-00-0.02-0.03-0.033.5700
01.511.7321.05055.0200
00000379.1400
1.4704.199.89310.71536.9900
00000475.8800
00000000
000.020.030.311.4500
00000000
00000000
00000000
00000000
000.020.030.311.4500
00000.285.0200
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Palantir Bioceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Palantir Bioceuticals's financial health and stability.

Assets

Palantir Bioceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Palantir Bioceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Palantir Bioceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Palantir Bioceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (k)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20102011201220132014201520212022
00000-200
00000000
00000000
00000000
000001,00000
00000000
00000000
00000000
00000000
00000000
00000000
00000000
00000000
00000000
00000000
--------
00000000
00000000
-0-0-0.01-0.01-0.12-0.6700
00000000

Palantir Bioceuticals stock margins

The Palantir Bioceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Palantir Bioceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Palantir Bioceuticals.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Palantir Bioceuticals's sales revenue. A higher gross margin percentage indicates that the Palantir Bioceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Palantir Bioceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Palantir Bioceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Palantir Bioceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Palantir Bioceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Palantir Bioceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Palantir Bioceuticals Margin History

Palantir Bioceuticals Gross marginPalantir Bioceuticals Profit marginPalantir Bioceuticals EBIT marginPalantir Bioceuticals Profit margin
20220 %0 %0 %
20210 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %

Palantir Bioceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Palantir Bioceuticals earnings per share therefore indicates how much revenue Palantir Bioceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Palantir Bioceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Palantir Bioceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Palantir Bioceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Palantir Bioceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Palantir Bioceuticals Revenue, EBIT and net profit per share

DatePalantir Bioceuticals Sales per SharePalantir Bioceuticals EBIT per sharePalantir Bioceuticals Earnings per Share
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20150 undefined-0.03 undefined-0.03 undefined
20140 undefined-0 undefined-0 undefined
20130 undefined-0 undefined-0 undefined
20120 undefined-0 undefined-0 undefined
20110 undefined-0 undefined-0 undefined
20100 undefined-0 undefined-0 undefined

Palantir Bioceuticals business model

IFAN Financial Inc is a company based in Las Vegas, Nevada. It originated in 1998 with the founding of iCARD Systems, specializing in prepaid cards. In 2007, the company changed its name to IFAN Financial Inc and expanded its business. The business model of IFAN Financial Inc focuses on providing financial services and technologies. The company specializes in various fields, including payment processing, mobile payment solutions, e-commerce, point-of-sale systems, and ethical investments. One important division of the company is IFAN Payment Systems, which offers a wide range of payment processing and payment solutions. The solutions can be used both online and offline. One particular feature is that IFAN Payment Systems provides fast transaction processing while maintaining high security standards. IFAN Financial Inc also has a division in the mobile services sector, which includes providing mobile payment solutions and mobile banking services. These services can be accessed through mobile devices and are tailored to the needs of modern customers who use mobile devices to manage and monitor their finances. Another important area in which IFAN Financial Inc operates is e-commerce. The focus is on providing technical solutions that allow customers to securely and effectively buy and sell goods and services online. The company has also developed a solution for online marketplaces, making it easier for merchants to register and sell on multiple platforms. The point-of-sale solutions of IFAN Financial Inc enable secure payments at retail terminals. The company offers a wide range of products, including POS hardware and POS software. These solutions are particularly designed to speed up transaction processing and increase customer satisfaction. Another important aspect of the company is ethical investing. IFAN Financial Inc advocates for ethical investments that have profit-oriented goals but do not come at the expense of other people or the environment. The company identifies investments that align with its portfolio of ethical investment products. Overall, IFAN Financial Inc has a wide portfolio of services and products tailored to the needs of customers. The company strives to provide customers with a secure and effective payment system that helps them manage their finances and optimize their businesses. The company has been in business since 1998 and thus has extensive experience in the financial sector. Palantir Bioceuticals is one of the most popular companies on Eulerpool.com.

Palantir Bioceuticals SWOT Analysis

Strengths

IFAN Financial Inc has several strengths that contribute to its success in the market. Firstly, the company has a strong financial position, allowing it to withstand market fluctuations and invest in growth opportunities. Additionally, IFAN Financial Inc boasts a diverse product and service portfolio, catering to the evolving needs of its customers. The company also benefits from a strong brand reputation, built on its commitment to quality and customer satisfaction.

Weaknesses

While IFAN Financial Inc enjoys many strengths, it also faces certain weaknesses that can hinder its progress. One major weakness is the company's heavy reliance on a few key customers or markets, which puts it at risk of significant revenue loss in case of changes in customer preferences or economic downturns. Furthermore, IFAN Financial Inc may face challenges in effectively managing its rapid growth, including maintaining quality control and meeting customer demands.

Opportunities

There are several potential opportunities that IFAN Financial Inc can capitalize on to drive further growth and success. Firstly, the increasing demand for digital financial services presents a key opportunity for the company to expand its offerings and reach a wider customer base. Moreover, entering new geographic markets or diversifying its product line can help IFAN Financial Inc reduce its dependency on specific customers or regions, thereby mitigating risks. Collaboration with strategic partners or acquisitions may also open doors to innovative technologies and enhance the company's competitive advantage.

Threats

IFAN Financial Inc faces various threats that can affect its business operations and profitability. One significant threat is intense competition in the financial industry, with established players and new entrants vying for market share. This can lead to price wars and margin pressures, impacting IFAN Financial Inc's profitability. Additionally, the company must remain vigilant about changing regulatory requirements and compliance standards, as failure to comply can result in legal challenges and reputational damage. Lastly, external economic factors such as recessions or global financial crises pose a threat to the overall stability of the financial industry, which may impact IFAN Financial Inc's operations.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Palantir Bioceuticals Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Palantir Bioceuticals historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Palantir Bioceuticals shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Palantir Bioceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Palantir Bioceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Palantir Bioceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Palantir Bioceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Palantir Bioceuticals stock splits

In Palantir Bioceuticals's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Palantir Bioceuticals.

Palantir Bioceuticals shareholders

%
Name
Stocks
Change
Date
0 % McCarthy Asset Management, Inc0-180,0009/30/2021
1

Most common questions regarding Palantir Bioceuticals

What values and corporate philosophy does Palantir Bioceuticals represent?

IFAN Financial Inc represents values of innovation, transparency, and customer satisfaction. The company's corporate philosophy focuses on providing cutting-edge financial technology solutions to businesses and individuals. IFAN Financial Inc is committed to revolutionizing the way transactions are conducted by harnessing the power of digital technology. With a customer-centric approach, the company aims to enhance convenience, security, and efficiency in financial transactions. By constantly staying ahead in the industry, IFAN Financial Inc strives to empower its clients with seamless and secure financial solutions.

In which countries and regions is Palantir Bioceuticals primarily present?

IFAN Financial Inc is primarily present in the United States, with a focus on expanding its operations and market presence within North America.

What significant milestones has the company Palantir Bioceuticals achieved?

IFAN Financial Inc has achieved several significant milestones throughout its existence. With a focus on providing innovative financial technology solutions, the company has made notable progress in expanding its offerings and reaching new markets. Some key achievements include the successful launch of their mobile payments platform, which has gained traction within the financial industry. IFAN Financial Inc has also secured strategic partnerships with leading organizations, enhancing its market presence and positioning. Furthermore, the company's dedication to continuous improvement and delivering value to its clients has resulted in achieving steady growth and recognition in the realm of financial technology.

What is the history and background of the company Palantir Bioceuticals?

IFAN Financial Inc, founded in 2010, is a financial technology company specializing in mobile payment solutions. With a focus on innovation and convenience, IFAN provides secure and efficient mobile payment solutions to businesses and consumers. The company offers a wide range of services, including mobile wallet platforms, mobile commerce solutions, and mobile banking applications. IFAN has established strategic partnerships and collaborations with industry leaders to enhance its offerings and expand its market reach. With a strong history of technological advancements and a commitment to customer satisfaction, IFAN Financial Inc continues to be a leading player in the fintech industry.

Who are the main competitors of Palantir Bioceuticals in the market?

The main competitors of IFAN Financial Inc in the market include other financial technology (fintech) companies offering similar services and solutions. Some notable competitors of IFAN Financial Inc may include PayPal Holdings Inc, Square Inc, Stripe Inc, and Adyen NV. These companies also operate in the fintech industry, providing various payment processing solutions, mobile payment options, and online financial services.

In which industries is Palantir Bioceuticals primarily active?

IFAN Financial Inc primarily operates in the technology and financial services industries.

What is the business model of Palantir Bioceuticals?

The business model of IFAN Financial Inc revolves around providing innovative and comprehensive financial technology solutions. IFAN Financial specializes in creating secure and user-friendly mobile payment applications, allowing individuals and businesses to seamlessly transfer funds, make payments, and manage their finances efficiently. By leveraging cutting-edge technology and strategic partnerships, IFAN Financial aims to streamline payment processes, enhance customer experiences, and drive financial inclusion. Through its robust platform, IFAN Financial enables secure and convenient financial transactions, empowering individuals and businesses to embrace digital payment solutions for increased convenience and financial growth.

What is the P/E ratio of Palantir Bioceuticals 2025?

The P/E ratio cannot be calculated for Palantir Bioceuticals at the moment.

What is the P/S ratio of Palantir Bioceuticals 2025?

The P/S cannot be calculated for Palantir Bioceuticals currently.

What is the Quality Investing of Palantir Bioceuticals?

The Quality Investing for Palantir Bioceuticals is 1/10.

What is the revenue of Palantir Bioceuticals 2025?

The revenue cannot currently be calculated for Palantir Bioceuticals.

How high is the profit of Palantir Bioceuticals 2025?

The profit cannot currently be calculated for Palantir Bioceuticals.

What is the business model of Palantir Bioceuticals

IFAN Financial Inc is a technology and financial services company that focuses on the development and marketing of mobile applications and services for consumers. The company's business model is divided into several segments, including mobile applications, financial services, and consumer products. The company offers a variety of products and services, including mobile payment solutions, financing and lending, savings and investing, as well as consumer products such as food and shopping vouchers. IFAN Financial has a proprietary mobile platform used by users in the USA to receive and send payments from businesses and other users. The IFANpay mobile payment platform is one of IFAN Financial's key services. The platform allows for the purchase of goods and services, as well as money transfers to other users. The platform is user-friendly and easy to use, accepting multiple payment methods, and has a high level of security to protect user data. The company also offers services in financing and lending. IFAN Financial has partnered with Lendify Financial, a financial institution that provides peer-to-peer loans to consumers. The partnership allows IFAN Financial to provide its users with a platform to apply for and receive loans. The platform offers quick and easy loan pre-determinations and allows for fast loan disbursements. IFAN Financial also provides opportunities for saving and investing. The company has an agreement with peer-to-peer lending company Prosper Marketplace, which offers its users access to peer-to-peer investment opportunities. The platform offers a wide range of investment options, from conservative to risky, to meet the needs of users. In addition to its mobile payment and financial services, IFAN Financial also offers products and services for everyday consumer use. IFAN Rewards is a rewards program that gives users points for purchasing goods and services, which can be redeemed for food or shopping vouchers. This promotes user loyalty and strengthens the company's position in the market. Overall, IFAN Financial's business model is unique and comprehensive. The company has focused on the development and marketing of mobile applications and services for consumers, securing a significant place in the digital payment industry. With its commitment to user-friendliness, security, and reliability, IFAN Financial has established itself as a leading mobile payment platform in the USA.

What is the Palantir Bioceuticals dividend?

Palantir Bioceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Palantir Bioceuticals pay dividends?

The dividend cannot currently be calculated for Palantir Bioceuticals or the company does not pay out a dividend.

What is the Palantir Bioceuticals ISIN?

The ISIN of Palantir Bioceuticals is US45173B1017.

What is the Palantir Bioceuticals WKN?

The WKN of Palantir Bioceuticals is A12GSL.

What is the Palantir Bioceuticals ticker?

The ticker of Palantir Bioceuticals is IFAN.

How much dividend does Palantir Bioceuticals pay?

Over the past 12 months, Palantir Bioceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Palantir Bioceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Palantir Bioceuticals?

The current dividend yield of Palantir Bioceuticals is .

When does Palantir Bioceuticals pay dividends?

Palantir Bioceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Palantir Bioceuticals?

Palantir Bioceuticals paid dividends every year for the past 0 years.

What is the dividend of Palantir Bioceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Palantir Bioceuticals located?

Palantir Bioceuticals is assigned to the '-' sector.

Wann musste ich die Aktien von Palantir Bioceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Palantir Bioceuticals from 1/22/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/22/2025.

When did Palantir Bioceuticals pay the last dividend?

The last dividend was paid out on 1/22/2025.

What was the dividend of Palantir Bioceuticals in the year 2024?

In the year 2024, Palantir Bioceuticals distributed 0 USD as dividends.

In which currency does Palantir Bioceuticals pay out the dividend?

The dividends of Palantir Bioceuticals are distributed in USD.

All fundamentals about Palantir Bioceuticals

Our stock analysis for Palantir Bioceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Palantir Bioceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.